Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Notice of Results & Investor Presentation


Arix Bioscience PLC (ARIX)
Notice of Results & Investor Presentation

03-Aug-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


 

Arix Bioscience plc

 

Notice of Results & Investor Presentation

 

LONDON, 3 August 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, will announce its results for the six months ended 30 June 2022 on Wednesday 10 August 2022.

 

Analyst Briefing: 9:00am, Wednesday 10 August

 

Management will host a virtual analyst presentation followed by a Q&A session at 9:00am BST on Wednesday 10 August. Analysts wishing to join should register their interest by contacting [email protected].

 

Investor Presentation: 2:00pm, Wednesday 10 August

 

Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 2:00pm BST on Wednesday 10 August.

 

The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the 'Investor Meet Company' dashboard up until 9:00 a.m. on Wednesday 10 August or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/arix-bioscience-plc/register-investor

 

Investors who already follow Arix on the Investor Meet Company platform will automatically receive an invitation to the event.

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

[email protected]

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 



ISIN: GB00BD045071
Category Code: NOR
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 178861
EQS News ID: 1411893

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1411893&application_name=news&site_id=sharewise
Like: 0
Teilen
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Rechtlicher Hinweis

Kommentare